Physician profile
Vivek Modi
NPI 1316468812
$2,131.47
in general payments reported to CMS, 2019-2025
12 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $316 · 2023: $624 · 2024: $748 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $423.04 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System, Sapien 3 Ultra Resilia |
| Medtronic, INC. | $400.18 | 2023-2025 | Micra, Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.83 | 2021-2023 | Jardiance |
| Boston Scientific Corporation | $171.55 | 2024-2025 | Watchman Flx |
| Lantheus Medical Imaging, INC. | $163.38 | 2023-2024 | Definity |
| E.R. Squibb & Sons, L.L.C. | $155.22 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $137.52 | 2023-2025 | |
| Philips North America LLC | $123.54 | 2024 | (6342) Intrasight Integrated |
| Amgen INC. | $83.73 | 2023-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $56.18 | 2024 | |
| Bridgebio Pharma, INC. | $25.51 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $22.79 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.